Free Trial
NASDAQ:SANA

Sana Biotechnology Q2 2025 Earnings Results & Report

Sana Biotechnology logo
$2.36 -0.08 (-3.09%)
As of 12:17 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sana Biotechnology beat analyst earnings expectations in its Q2 2025 results, released August 11, 2025. The company reported EPS of -$0.16 versus the -$0.20 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
12:30 PM ET

Sana Biotechnology EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Sana Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sana Biotechnology Q2 2025 Earnings FAQ

Sana Biotechnology (NASDAQ:SANA) reported earnings of -$0.16 per share for Q2 2025, beating the consensus estimate of -$0.20. The report was announced on Monday, August 11, 2025.

Sana Biotechnology Earnings Headlines

Social Security’s trust fund runs short in 2032. Guess who controls Congress.
Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. After that, only about 78% of scheduled benefits can be paid unless Congress acts. Higher taxes, smaller checks or more borrowing are all on the table. The morning after Democrats took Congress, gold jumped almost 3% and silver jumped 4%. If you count on Social Security for any part of your retirement, a backup plan matters before 2032.tc pixel
Sana Biotechnology: A Shot At Diabetes
See More Sana Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email.

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement.

The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes. These are investigational programs, not approved products.

Sana conducts research and development in the United States, with locations including Seattle, South San Francisco and Cambridge. Its chief executive officer is Steve Harr.

View Sana Biotechnology Profile